Alto Neuroscience, Inc. $ANRO Stock Position Raised by Perceptive Advisors LLC

Perceptive Advisors LLC raised its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 1,048.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,784,393 shares of the company’s stock after purchasing an additional 1,629,027 shares during the period. Perceptive Advisors LLC owned 5.74% of Alto Neuroscience worth $31,762,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Commodore Capital LP bought a new position in shares of Alto Neuroscience in the 4th quarter valued at approximately $32,453,000. Vivo Capital LLC bought a new position in shares of Alto Neuroscience in the 4th quarter valued at approximately $18,433,000. Millennium Management LLC raised its stake in shares of Alto Neuroscience by 99.5% in the 4th quarter. Millennium Management LLC now owns 629,985 shares of the company’s stock valued at $11,214,000 after acquiring an additional 314,227 shares in the last quarter. Spruce Street Capital LP bought a new position in shares of Alto Neuroscience in the 4th quarter valued at approximately $3,967,000. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Alto Neuroscience by 14,567.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after acquiring an additional 211,222 shares in the last quarter.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO opened at $21.87 on Thursday. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average is $22.68 and its two-hundred day moving average is $19.72. The company has a market cap of $767.49 million, a P/E ratio of -9.04 and a beta of 1.22. Alto Neuroscience, Inc. has a 12 month low of $2.15 and a 12 month high of $28.44.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, equities analysts expect that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ANRO. Robert W. Baird cut their price objective on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday, March 16th. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Finally, Wedbush raised their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.25.

Alto Neuroscience Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.